| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
4 companies
Frazier Life Sciences Ix, L.P. is a 10% Owner at PHAT, with reported holdings spanning 4 companies. Recent filings cover 4 purchases and 0 sales. Those positions are worth an estimated $53.5M at current prices.
Frazier Life Sciences Ix, L.P.'s largest disclosed position is in MIRM as 10% Owner, worth about $53.5M. Net of sales, the recent Form 4 record there shows accumulation of 450,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 20, 2020 | TARS Tarsus Pharmaceuticals, Inc. | 10% Owner | Buy | 312,500 | $16.00 | $5,000,000.00 | +19.5% | |
| Mar 3, 2020 | PASG Passage Bio, Inc. | 10% Owner | Buy | 550,000 | $18.00 | $9,900,000.00 | +12.3% | |
| Oct 29, 2019 | PHAT Phathom Pharmaceuticals, Inc. | 10% Owner | Buy | 1,052,631 | $19.00 | $19,999,989.00 | +16.9% | |
| Jul 22, 2019 | MIRM Mirum Pharmaceuticals, Inc. | 10% Owner | Buy | 450,000 | $15.00 | $6,750,000.00 | +14.4% |